Blood pressure (BP) transducers are the sensors that convert biological signals into electrical analogue signals. Although, pressure transducers are most commonly used for invasive monitoring of arterial and venous pressures, they can also be used to measure intracranial and intra-abdominal pressures. Some Blood Pressure (BP) Transducers are intended to provide consistent and accurate measurements of arterial and venous blood pressure in animals of all sizes.
The transducer can be used to monitor central venous pressure if the result of a physical examination may be too imprecise or when it is considered useful to follow trends, such as a gradual decrease in central venous pressure.
Global Blood Pressure Transducers Market – Dynamics
The increasing prevalence of hypertension (high blood pressure) may drive the growth of the global blood pressure transducers market. For instance, according to Centers of Disease Control and Prevention, in 2018, nearly half a million deaths in the U.S. included hypertension as a primary cause. Moreover, according to the same source, approximately 108 million adults had hypertension or were prescribed medication for hypertension in the U.S.
Increasing launches of blood pressure measuring devices is expected to boost global blood pressure transducers market growth. For instance, on May 26, 2021, Biobeat, a global leader in wearable remote patient monitoring solutions for the healthcare continuum, launched a new wearable and continuous ambulatory blood pressure monitoring (ABPM) chest-monitoring device. ABPM can serve as a critical indicator of patient’s health by continuously tracking patient’s cardiac data in real-life settings outside the physician's office to provide an accurate, holistic, and unbiased picture of patient’s health.
Key players are focusing on strategies such as mergers, agreements, and acquisitions which is expected to propel the global blood pressure transducers market over the forecast period. For instance, on June 25, 2020, Infineon Technologies AG, a German-based manufacturer of semiconductors, announced that its Silicon Valley Innovation Center (SVIC) had entered into an agreement with Blumio Inc., a company focused on creating sensors and systems that improves people’s health and wellness, to co-develop a wearable, non-invasive blood pressure sensor based on Infineon's XENSIV radar chipset.
These factors are expected to support global blood pressure transducers market growth over the forecast period.
Global Blood Pressure Transducers Market – Regional Insights
North America is estimated to account for the largest share in the global blood pressure transducers market in the forecast period owing to the expansion of applications of medical devices for the measurement of blood pressure and other human vitals. For instance, on January 12, 2021, Valencell, an innovator in transforming the science of wearable biometrics, announced that its cuff-less blood pressure (BP) technology for wearable’s can now be used in devices worn on the finger and wrist. The technology, which extends cuff-like BP accuracy to other parts of the body, was first released for hearable, hearing aids, and other ear-based devices in January 2020. This latest advancement significantly increases the number of device form factors in which the technology can be embedded, including smart watches, fitness bands, patches, and pulse oximeter finger clips. These factors are expected to support global blood pressure transducers market growth over the forecast period.
Global Blood Pressure Transducers Market –Taxonomy
By Product Type:
By End User
- Ambulatory surgery centers
- Specialty clinics
- Diagnostic laboratories
- North America
- Asia Pacific
- Latin America
- Middle East
Global Blood Pressure Transducers Market – Competitive landscape
Key players involved in the global blood pressure transducers market include Infineon Technologies AG, Blumio, Inc., Biobeat Technologies, Henleys Medical Supplies Ltd, Lepu Medical Technology (Beijing ) Co., ICU Medical, Inc., Edwards Lifesciences, SunTech Medical, Inc., B. Braun Holding GmbH & Co., Valencell, Inc., and Smiths Medical, Inc. (Smiths Group)